Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Krystal Biotech, Inc.    KRYS

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2020 10/14/2020 10/15/2020 10/16/2020 10/19/2020 Date
50.97(c) 50.06(c) 51.08(c) 51.62(c) 48.85(c) Last
65 720 56 994 53 264 59 506 263 029 Volume
-1.70% -1.79% +2.04% +1.06% -5.37% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -32,5 M - -
Net cash position 2020 253 M - -
P/E ratio 2020 -28,4x
Yield 2020 -
Sales 2021 61,3 M - -
Net income 2021 -61,4 M - -
Net cash position 2021 171 M - -
P/E ratio 2021 -17,1x
Yield 2021 -
Capitalization 961 M 961 M -
EV / Sales 2020 -
EV / Sales 2021 12,9x
Nbr of Employees 52
Free-Float 72,5%
More Financials
Company
Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop... 
More about the company
Notations Surperformance© of Krystal Biotech, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about KRYSTAL BIOTECH, INC.
10/16KRYSTAL BIOTECH : Announces Departure of Chief Commercial Officer
BU
10/08KRYSTAL BIOTECH : to Present Pre-clinical Data Highlighting KB301 for Aesthetic ..
BU
10/01KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/24KRYSTAL BIOTECH : to Present at Upcoming Investor Conferences
BU
09/09Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Con..
GL
09/09KRYSTAL BIOTECH : to Present at HC Wainwright and Morgan Stanley Healthcare Conf..
AQ
08/25Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aes..
GL
08/17Krystal Biotech's KB407 Granted Orphan Drug Designation by the FDA to Treat P..
GL
08/10KRYSTAL BIOTECH, INC. : Results of Operations and Financial Condition, Financial..
AQ
08/10Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Up..
GL
08/10KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
07/30Krystal Biotech to Present at the William Blair BioTech Conference
GL
07/28Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene G..
GL
07/20Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and ..
GL
06/08KRYSTAL BIOTECH : to Present at the Goldman Sachs 41st Annual Global Healthcare ..
AQ
More news
News in other languages on KRYSTAL BIOTECH, INC.

- No features available -

More news
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 81,22 $
Last Close Price 48,85 $
Spread / Highest target 135%
Spread / Average Target 66,3%
Spread / Lowest Target 10,5%
EPS Revisions
Managers
NameTitle
Krish S. Krishnan Chairman, President & Chief Executive Officer
Suma M. Krishnan Chief Operating Officer & Director
George Chen Manager-Information Technology & CSV
Dan S. Janney Lead Independent Director
Dino A. Rossi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KRYSTAL BIOTECH, INC.-6.79%1 015
GILEAD SCIENCES, INC.-6.79%77 731
REGENERON PHARMACEUTICALS55.31%63 111
VERTEX PHARMACEUTICALS0.71%56 803
WUXI APPTEC CO., LTD.60.41%39 207
BEIGENE, LTD.81.90%28 693